Wednesday, July 8, 2026

Patent intelligence · US

US 8084498

Ketone compounds and compositions for cholesterol management and related uses

granted A61PA61P1/00A61P1/16A61P1/18
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 5
Applicant portfolio 55
Patent details — US 8084498
Jurisdiction
US
Status
granted
Grant date
Dec 27, 2011
Expiration
Dec 22, 2031
Claims
14
CPC classes
A61P, A61P1/00, A61P1/16, A61P1/18
View on Google Patents ↗

Quick answer

US 8084498 (Ketone compounds and compositions for cholesterol management and related uses) is held by Esperion Therapeutics, Inc.. Status: granted. Granted Dec 27, 2011. Expires Dec 22, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
14
CPC classes
A61P, A61P1/00, A61P1/16, A61P1/18, A61P13/12, A61P15/10

More from Esperion Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12404227

    Methods of making bempedoic acid and compositions of the same

    Esperion Therapeutics, Inc. · Expires Aug 28, 2045

    granted
  2. US 12398087

    Methods of making bempedoic acid and compositions of the same

    Esperion Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  3. US 12344578

    Salt forms of bempedoic acid and methods for using the same

    Esperion Therapeutics, Inc. · Expires Jun 26, 2045

    granted
  4. US 11987548

    Methods of making bempedoic acid and compositions of the same

    Esperion Therapeutics, Inc. · Expires May 16, 2044

    granted
  5. US 11926584

    Methods of making bempedoic acid and compositions of the same

    Esperion Therapeutics, Inc. · Expires Mar 7, 2044

    granted
  6. US 11760714

    Methods of making bempedoic acid and compositions of the same

    Esperion Therapeutics, Inc. · Expires Sep 14, 2043

    granted
  7. US 11744816

    Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

    Esperion Therapeutics, Inc. · Expires Aug 31, 2043

    granted
  8. US 11613511

    Methods of making bempedoic acid and compositions of the same

    Esperion Therapeutics, Inc. · Expires Mar 23, 2043

    granted

Frequently asked questions

What is US patent 8084498?

US 8084498 (Ketone compounds and compositions for cholesterol management and related uses) is held by Esperion Therapeutics, Inc.. Status: granted. Granted Dec 27, 2011. Expires Dec 22, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8084498?

Esperion Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 55 pharmaceutical patents for this assignee.

When does US 8084498 expire?

Our index shows an expiration date of Dec 22, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.